Small-Molecule Inhibitors of PARPs: From Tools for Investigating ADP-Ribosylation to Therapeutics.
Curr Top Microbiol Immunol
; 420: 211-231, 2019.
Article
en En
| MEDLINE
| ID: mdl-30242511
ABSTRACT
Over the last 60 years, poly-ADP-ribose polymerases (PARPs, 17 family members in humans) have emerged as important regulators of physiology and disease. Small-molecule inhibitors have been essential tools for unraveling PARP function, and recently the first PARP inhibitors have been approved for the treatment of various human cancers. However, inhibitors have only been developed for a few PARPs and in vitro profiling has revealed that many of these exhibit polypharmacology across the PARP family. In this review, we discuss the history, development, and current state of the field, highlighting the limitations and opportunities for PARP inhibitor development.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Poli(ADP-Ribosa) Polimerasas
/
Inhibidores de Poli(ADP-Ribosa) Polimerasas
/
ADP-Ribosilación
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Curr Top Microbiol Immunol
Año:
2019
Tipo del documento:
Article
País de afiliación:
Estados Unidos